Purpose: Hematopoietic stem cell transplantation (HSCT) has been an important method of treatment in the advance of pediatric acute lymphoblastic leukemia (ALL). The indications for HSCT are evolving and require updated establishment. In this study, we aimed to investigate the efficacy of HSCT on the treatment outcome of pediatric ALL, considering the indications for HSCT and subgroups.
Materials And Methods: A retrospective analysis was conducted on ALL patients diagnosed and treated at a single center. Risk groups were categorized based on age at diagnosis, initial white blood cell count, disease lineage (B/T), and cytogenetic study results. Data on the patients' disease status at HSCT and indications of HSCT were collected. Indications for HSCT were categorized as upfront HSCT at 1st complete remission, relapse, and refractory disease.
Results: Among the 549 screened patients, a total of 418 patients were included in the study; B-ALL (n=379) and T-ALL (n=39). HSCT was conducted on a total of 106 patients (25.4%), with a higher frequency as upfront HSCT in higher risk groups and specific cytogenetics. The overall survival (OS) was significantly better when done upfront than in relapsed or refractory state in T-ALL patients (p=0.0016). The KMT2A-rearranged ALL patients showed superior event-free survival (p=0.0023) and OS (p=0.0221) when HSCT was done as upfront treatment.
Conclusion: HSCT had a substantial positive effect in a specific subset of pediatric ALL. In particular, frontline HSCT for T-ALL and KMT2A-rearranged ALL offered a better prognosis than when HSCT was conducted in a relapsed or refractory setting.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4143/crt.2024.155 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
HCT in the widening spectrum of congenital immunodeficiencies.
Curr Opin Hematol
January 2025
Instituto de Pesquisa Pele Pequeno Principe/Faculdades Pequeno Principe, Hospital de Clinicas da Universidade Federal do Parana, Curitiba, Brazil.
Purpose Of Review: Hematopoietic stem cell transplantation (HSCT) and inborn errors of immunity (IEI) have been closely linked since transplantation was first used to cure severe combined immunodeficiency (SCID) in 1968. Since then, novel genes and diseases have been continually added to the ongoing list of IEI, and new data on indications and outcomes have emerged. We review recent data and progress in the field of hematopoietic cell transplantation (HCT) for IEI including new diseases and complications.
View Article and Find Full Text PDFElevation of NT-proBNP Levels in Pediatric and Young Adult Hematopoietic Stem Cell Transplant Patients with Endotheliopathy.
Pediatr Rep
October 2024
Division of Pediatric Critical Care Medicine, St. Jude Children's Research Hospital, 262 Danny Thomas Place, MS 734 Room IA3309, Memphis, TN 38105, USA.
Background/objectives: Hematopoietic stem cell transplantation (HSCT) in pediatric and young adult (YA) patients can lead to endotheliopathy, such as thrombotic microangiopathy (TMA), sinusoidal obstruction syndrome (SOS), and diffuse alveolar hemorrhage (DAH). Natriuretic peptides have been studied as markers of endotheliopathy and critical illness. We hypothesized that an elevation in NT-proBNP was associated with the development of endotheliopathy (DAH, SOS, or TMA) in the first 100 days following HSCT in pediatric and YA patients.
View Article and Find Full Text PDFHuman papillomavirus vaccine uptake among adolescent survivors of hematopoietic stem cell transplant.
J Cancer Surviv
November 2024
Division of Pediatric and Adolescent Gynecology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.
Article Synopsis
- The study aimed to assess how many adolescents got the HPV vaccine after undergoing hematopoietic stem cell transplant (HSCT) between 2015 and 2022.
- Among 119 patients evaluated, 55.5% received at least one HPV vaccine dose post-transplant, with 68.2% completing two or more doses.
- The findings indicated that HPV vaccine uptake after HSCT was lower than other vaccines and prior vaccination didn’t significantly influence post-HSCT vaccination decisions, highlighting the need for better vaccination strategies in this high-risk group.
Paving the Road for Haematopoietic Stem Cell Transplantation in the United Arab Emirates: A Single Centre's Experience.
J Blood Med
November 2024
Medical Oncology Department, Burjeel Medical City, Abu Dhabi, United Arab Emirates.
Background: Despite its long-term history, haematopoietic stem cell transplantation (HSCT) still faces challenges in several countries under development and especially in the private health sector.
Objectives Design And Methods: In this retrospective analysis, we present our experience and the results of 48 adult patients who underwent HSCT (autologous 37, allogeneic 9) at a private-sector hospital in Abu Dhabi, United Arab Emirates (UAE). The main indications were multiple myeloma and acute myeloid leukaemia in the autologous and allogeneic setting, respectively.
Impact of Persistent Alopecia on Quality of Life in Childhood Cancer and Transplant Survivors.
Pediatr Blood Cancer
February 2025
Harvard Medical School, Boston, Massachusetts, USA.
Background: While alopecia associated with chemotherapy, radiation, or hematopoietic stem-cell transplant (C/R/HSCT) is transient in most children, prior reports indicate nearly one in seven childhood cancer survivors suffer from persistent alopecia after their treatment is completed. The objective of our study was to better characterize the impact of C/R/HSCT-associated persistent alopecia on patient quality of life.
Procedure: A cross-sectional cohort study of patients with a history of C/R/HSCT who were seen at Dana Farber Cancer Institute/Boston Children's Hospital Dermatology from August 2023 to February 2024 for any indication was conducted.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!